Figure 2
Survival outcomes after erlotinib treatment. Kaplan–Meier estimates of progression-free survival (a) and overall survival (b). Dot censored case at the data cut-off point.
Figure 2 | BMC Research Notes
Survival outcomes after erlotinib treatment. Kaplan–Meier estimates of progression-free survival (a) and overall survival (b). Dot censored case at the data cut-off point.